Squadron Capital Management »

Cue Biopharma shares owned by Squadron Capital Management

Quarter-by-quarter ownership of Cue Biopharma (CUE) shares owned by Squadron Capital Management from 13F filings

Historical chart of Squadron Capital Management investment in Cue Biopharma

Tip: Access up to 7 years of quarterly data

All positions including Cue Biopharma held by Squadron Capital Management consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Cue Biopharma by Squadron Capital Management

Quarter filed Position value Share count Share price at filing
2026-06-30 $1.6M 50k 31.56

More positions owned by Squadron Capital Management

Relmada Therapeutics (RLMD)
C4 Therapeutics Com Stk (CCCC)
Cogent Biosciences (COGT)
Zentalis Pharmaceuticals Call Option (ZNTL)
Kodiak Sciences (KOD)
Relay Therapeutics (RLAY)
Edgewise Therapeutics (EWTX)
Maze Therapeatics (MAZE)
Bioage Labs Call Option (BIOA)
Inventiva Sa Ads (IVA)
Adlai Nortye Sponsored Ads (ANL)
Compass Pathways Sponsored Ads (CMPS)
Enliven Therapeutics (ELVN)
Rezolute Com New (RZLT)
Arrivent Biopharma Call Option (AVBP)

View all positions for Squadron Capital Management

Top funds holding Cue Biopharma

Bleichroeder
Vanguard Capital Management
Ikarian Capital
ADAR1 Capital Management
Lion Point Capital
Squadron Capital Management
Belvedere Trading
Citadel Advisors
Vanguard Fiduciary Trust
Texas Capital Bank Wealth Management Services
Renaissance Technologies
Robertson Stephens Wealth Management
Advisory Research
Stifel Financial
Angeles Wealth Management

View all funds holding Cue Biopharma